Skip to main content
SpringerLink
Log in

Bacteriophage therapy: are we running before we have learned to walk?

  • Letter to the Editor
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Suh GA, Lodise TP, Tamma PD et al (2022) Considerations for the use of phage therapy in clinical practice. Antimicrob Agents Chemother 66:e0207121

    Article  PubMed  Google Scholar 

  2. Corbellino M, Kieffer N, Kutateladze M et al (2020) Eradication of a multidrug-resistant, carbapenemase-producing Klebsiella pneumoniae isolate following oral and intra-rectal therapy with a custom made, lytic bacteriophage preparation. Clin Infect Dis 70(9):1998–2001. https://doi.org/10.1093/cid/ciz782

    Article  CAS  PubMed  Google Scholar 

  3. Chan BK, Abedon ST (2015) Bacteriophages and their enzymes in biofilm control. Curr Pharm Des 21(1):85–99

    Article  CAS  PubMed  Google Scholar 

  4. Principi N, Silvestri E, Esposito S (2019) Advantages and limitations of bacteriophages for the treatment of bacterial infections. Front Pharmacol 8(10):513. https://doi.org/10.3389/fphar.2019.00513

    Article  Google Scholar 

  5. Gurney J, Pradier L, Griffin JS, Gougat-Barbera C, Chan BK, Turner PE, Kaltz O, Hochberg ME (2020) Phage steering of antibiotic-resistance evolution in the bacterial pathogen, Pseudomonas aeruginosa. Evol Med Public Health 2020(1):148–157. https://doi.org/10.1093/emph/eoaa026

    Article  PubMed  PubMed Central  Google Scholar 

  6. Jault P et al (2019) Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis 19(1):35–45

    Article  PubMed  Google Scholar 

  7. Depalma BJ, Nandi S, Chaudhry W et al (2022) Assessment of staphylococcal clinical isolates from periprosthetic joint infections for potential bacteriophage therapy. J Bone Joint Surg Am 104(8):693–699

    Article  PubMed  Google Scholar 

  8. Berryhill BA, Huseby DL, McCall IC, Hughes D, Levin BR (2021) Evaluating the potential efficacy and limitations of a phage for joint antibiotic and phage therapy of Staphylococcus aureus infections. Proc Natl Acad Sci U S A 118(10):e2008007118

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Azam AH, Tanji Y (2019) Peculiarities of Staphylococcus aureus phages and their possible application in phage therapy. Appl Microbiol Biotechnol 103(11):4279–4289

    Article  CAS  PubMed  Google Scholar 

  10. Doub JB, Urish K, Lee M, Fackler J (2022) Impact of bacterial phenotypic variation with bacteriophage therapy: a pilot study with prosthetic joint infection isolates. Int J Infect Dis 119:44–46. https://doi.org/10.1016/j.ijid.2022.03.022

    Article  CAS  PubMed  Google Scholar 

  11. Mistretta N et al (2019) Glycosylation of Staphylococcus aureus cell wall teichoic acid is influenced by environmental conditions. Sci Rep 9(1):1–11

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, 725 west Lombard Street, Baltimore, MD, 21201, USA

    James B. Doub

Authors
  1. James B. Doub
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

J. B. D. devised the editorial and wrote the first draft and revisions.

Corresponding author

Correspondence to James B. Doub.

Ethics declarations

Competing interests

The author declares no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Doub, J.B. Bacteriophage therapy: are we running before we have learned to walk?. Eur J Clin Microbiol Infect Dis 42, 1281–1283 (2023). https://doi.org/10.1007/s10096-023-04658-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-023-04658-x

Search

Navigation